Synthetic Biologics Inc (NYSEMKT:SYN) has received a consensus recommendation of “Buy” from the nine ratings firms that are covering the firm. One equities research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $5.22.

Several analysts have weighed in on SYN shares. FBR & Co reissued a “buy” rating on shares of Synthetic Biologics in a research note on Friday, August 5th. Zacks Investment Research raised shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Tuesday, August 9th. BTIG Research started coverage on shares of Synthetic Biologics in a research note on Thursday, August 25th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Griffin Securities set a $5.80 price target on shares of Synthetic Biologics and gave the stock a “buy” rating in a research note on Wednesday, August 31st.

An institutional investor recently raised its position in Synthetic Biologics stock. UBS Group AG increased its position in Synthetic Biologics Inc (NYSEMKT:SYN) by 378.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 288,367 shares of the company’s stock after buying an additional 228,037 shares during the period. UBS Group AG owned approximately 0.32% of Synthetic Biologics worth $680,000 at the end of the most recent reporting period.

Shares of Synthetic Biologics (NYSEMKT:SYN) traded down 1.141% during mid-day trading on Monday, hitting $0.875. The stock had a trading volume of 1,140,545 shares. The firm’s market capitalization is $80.65 million. Synthetic Biologics has a 1-year low of $0.85 and a 1-year high of $3.09. The stock’s 50-day moving average is $1.45 and its 200 day moving average is $1.73.

Synthetic Biologics (NYSEMKT:SYN) last posted its quarterly earnings results on Tuesday, November 1st. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Equities research analysts predict that Synthetic Biologics will post ($0.35) EPS for the current fiscal year.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Stock Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related stocks with our FREE daily email newsletter.